市場調査レポート
商品コード
1263188

医薬品受託製造の世界市場:サービス別 (医薬品 (API、FDF (錠剤、カプセル、注射剤))、生物製剤 (API、FDF)、医薬品開発)・エンドユーザー別 (大手製薬企業、中小製薬企業、ジェネリック医薬品企業)・地域別の将来予測 (2028年まで)

Pharmaceutical Contract Manufacturing Market by Service (Pharmaceutical (API, FDF - Tablet, Capsule, Injectable)), Biologic (API, FDF), Drug Development), End User (Big Pharma, Small & Medium-sized Pharma, Generic Pharma) - Global Forecast to 2028

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 279 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
医薬品受託製造の世界市場:サービス別 (医薬品 (API、FDF (錠剤、カプセル、注射剤))、生物製剤 (API、FDF)、医薬品開発)・エンドユーザー別 (大手製薬企業、中小製薬企業、ジェネリック医薬品企業)・地域別の将来予測 (2028年まで)
出版日: 2023年04月19日
発行: MarketsandMarkets
ページ情報: 英文 279 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の医薬品受託開発・製造の市場規模は、2023年の1,765億米ドルから、2028年には2,583億米ドルに達し、予測期間中のCAGRは7.9%になると予想されています。

低コストによるジェネリック医薬品の需要の増加や、ブロックバスター医薬品の特許切れが迫っているなどの要因により、企業はコア機能に集中するようになり、それがCDMOサービスの需要を支え、市場の成長を加速しています。

"生物製剤製造サービスのセグメントは、予測期間中 (2023年~2028年) に最も高いCAGRで成長する"

生物製剤製造サービスのセグメントは、予測期間中に最も高いCAGRで成長すると予測されています。この成長は、生物製剤の需要の高まり、標的薬物療法、細胞・遺伝子治療パイプライン研究の増加などに起因しています。これらの要因が、セグメント別の成長に好影響を与えると思われます。

"大手製薬企業のセグメントは、予測期間中 (2023年~2028年) に最も高いCAGRで成長する"

医薬品受託開発・製造市場では、2022年に、大手製薬企業のセグメントが圧倒的なシェアを占めています。このセグメントの大きなシェアは、製薬会社が新分子の発見と開発のための研究開発の増加といった中核的な活動に重点を置くようになり、製造サービスの外部委託を後押ししていることに起因しています。これは、市場成長を予測させる主要な要因の一つです。

"アジア太平洋地域は、より速いペースで成長する"

2022年、北米は医薬品受託開発・製造市場で圧倒的なシェアを占めています。同地域の優位性は、同地域の大手企業の存在や、医薬品受託開発・製造の継続的な研究活動など、さまざまな要因に起因しています。アジア太平洋地域は、個別化治療に対する関心増大、ジェネリック医薬品に対する政府の取り組み強化、医薬品受託開発・製造市場における新規参入企業の出現など、さまざまな要因により、より速いペースで成長すると思われます。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • バリューチェーン分析
  • エコシステム分析
  • 技術分析
  • ポーターのファイブフォース分析
  • 規制分析
  • 主な会議とイベント (2022年~2023年)
  • 主な利害関係者と購入基準
  • 顧客のビジネスに影響を与える動向/混乱
  • ANDAの承認

第6章 医薬品受託開発・製造市場:サービス別

  • イントロダクション
  • 医薬品製造サービス
    • 医薬品API (原薬) 製造サービス
    • 医薬品FDF (完成剤形) 製造サービス
  • 医薬品開発サービス
  • 生物製剤製造サービス
    • 生物製剤API (原薬) 製造サービス
    • 生物製剤FDF (完成剤形) 製造サービス

第7章 医薬品受託開発・製造市場:エンドユーザー別

  • イントロダクション
  • 大手製薬企業
  • 中小製薬企業
  • ジェネリック医薬品企業
  • その他のエンドユーザー

第8章 医薬品受託開発・製造市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スイス
    • ポーランド
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • ラテンアメリカ
    • ブラジル
    • その他ラテンアメリカ
  • 中東・アフリカ

第9章 競合情勢

  • 概要
  • 主要企業の戦略
  • 収益シェア分析
  • 市場シェア分析
  • 主要企業の企業評価クアドラント (2022年)
  • 上位25社の競合ベンチマーキング
  • スタートアップ/中小企業向けの企業評価クアドラント (2022年)
  • スタートアップ/中小企業の競合ベンチマーキング
  • 競合シナリオと動向

第10章 企業プロファイル

  • 主要企業
    • THERMO FISHER SCIENTIFIC, INC.
    • CATALENT, INC.
    • LONZA GROUP
    • ABBVIE, INC.
    • WUXI APPTEC
    • EVONIK INDUSTRIES AG
    • SAMSUNG BIOLOGICS
    • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • SIEGFRIED HOLDING AG
    • FUJIFILM HOLDINGS CORPORATION
    • EUROFINS SCIENTIFIC
    • PIRAMAL PHARMA SOLUTIONS
    • RECIPHARM AB
    • ALMAC GROUP
    • VETTER PHARMA
  • その他の企業
    • DELPHARM HOLDINGS
    • YUHAN CORPORATION
    • CURIA GLOBAL, INC.
    • CHARLES RIVER LABORATORIES
    • LANNETT COMPANY, INC.
    • CAMBREX CORPORATION
    • FAMAR HEALTHCARE SERVICES
    • SYNGENE INTERNATIONAL LIMITED (BIOCON LIMITED)
    • SAI LIFE SCIENCES LIMITED
    • PCI PHARMA SERVICES

第11章 付録

目次
Product Code: PH 7263

The global pharmaceutical contract development and manufacturing market size is projected to reach USD 258.3 billion by 2028 from USD 176.5 billion in 2023, at a CAGR of 7.9% during the forecast period. Factors such as increasing demand for generics due to their low cost and the looming patent expiry of blockbuster medications have pushed companies to focus on core functions, supporting the demand for CDMO services, and driving the market growth at a faster pace.

"The biologic manufacturing service segment is likely to grow at the highest CAGR during the forecast period of 2023-2028."

On the basis of service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing service, drug development service, and biologic manufacturing service. The biologic manufacturing service segment is projected to grow at the highest CAGR during the forecast period. The growth is attributed to the rising demand for biologics, targeted drug therapies, and increase in the number cell & gene therapy pipeline studies. These factors are likely to have a positive impact on segmental growth.

"The big pharmaceutical companies segment is likely to grow at the highest CAGR during the forecast period of 2023-2028."

Based on end user, the pharmaceutical contract development and manufacturing market is segmented into big pharmaceutical companies, small and midsized pharmaceutical companies, generic pharmaceutical companies, and other end users (Academic Institutes, Small CDMOs, and CROs). The big pharmaceutical companies segment held a dominant share of the pharmaceutical contract development and manufacturing market, in 2022. The large share of this segment is attributed to the growing focus of pharma giants on core activities like increasing R&D for the discovery & development of new molecules, pushing them to outsource the manufacturing services. This is one of the major factors anticipated to project market growth.

"Asia Pacific region is likely to grow at a faster pace."

The pharmaceutical contract development and manufacturing market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the dominant share of the pharmaceutical contract development and manufacturing market. The dominance of the region is attributable to various factors such as the presence of leading players in the region coupled with the ongoing research activities of pharmaceutical contract development and manufacturing. Asia Pacific region is likely to grow at a faster pace owing to various factors such as the growing awareness of personalized therapeutics, rising government initiatives for generic medicines in the region, and the emergence of new market players in the pharmaceutical contract development and manufacturing market.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 60%, and Demand Side - 40%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 25%, Executives- 15%, Other -15.0%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

Lists of Companies Profiled in the Report:

  • Thermo Fisher Scientific, Inc. (US)
  • Catalent, Inc. (US)
  • Lonza Group (Switzerland)
  • AbbVie, Inc. (US)
  • WuXi AppTec (China)
  • Evonik Industries AG (Germany)
  • Samsung Biologics. (South Korea)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Siegfried Holding AG (Switzerland)
  • Piramal Pharma Solutions (India)
  • Recipharm AB. (Sweden)
  • Eurofins Scientific (Luxembourg)
  • FUJIFILM Holdings Corporation (Japan)
  • Almac Group (UK)
  • Vetter Pharma (Germany)
  • Delpharm Holdings (France)
  • Yuhan Corporation (South Korea)
  • Curia Global, Inc. (US)
  • Charles River Laboratories. (US)
  • Lannett Company, Inc. (US)
  • Cambrex Corporation. (US)
  • FAMAR Healthcare Services (France)
  • Biocon Limited (India)
  • Sai Life Sciences Limited (India)
  • PCI Pharma Services (US).

Research Coverage:

This report provides a detailed picture of the pharmaceutical contract development and manufacturing market. It aims at estimating the size and future growth potential of the market across different segments, such as service, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical contract development and manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increased investment in precision medicines, Patent expiry & increasing demand for generic drugs, High cost of in-house drug development, Investments in advanced manufacturing technologies by CDMOs), restraints (Varying regulatory requirements across various regions), opportunities (Rising demand for cell & gene therapies, Growing inclination toward one-stop-shop model, Market expansion in emerging countries, Growth of nuclear medicine), and challenges (Introduction of serialization, Intellectual property risk) influencing the growth of pharmaceutical contract development and manufacturing market.
  • Service Development/Innovation: Detailed insights on newly launched services, and technological assessment of the pharmaceutical contract development and manufacturing market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the pharmaceutical contract development and manufacturing market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the pharmaceutical contract development and manufacturing market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group (Switzerland), AbbVie, Inc. (US), WuXi AppTec (China) and among others in the pharmaceutical contract development and manufacturing market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 STAKEHOLDERS
  • 1.7 LIMITATIONS
  • 1.8 SUMMARY OF CHANGES
  • 1.9 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
    • FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    • 2.2.2 SEGMENT ASSESSMENT (BY SERVICE AND END USER)
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • FIGURE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: CAGR PROJECTIONS, 2023-2028
    • FIGURE 9 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 IMPACT ANALYSIS OF RECESSION ON PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024-2027 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2027 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 11 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD BILLION)
    • FIGURE 12 BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION)
    • FIGURE 13 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    • FIGURE 14 GEOGRAPHICAL SNAPSHOT: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET

4 PREMIUM INSIGHTS

  • 4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET OVERVIEW
    • FIGURE 15 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE & COUNTRY (2022)
    • FIGURE 16 PHARMACEUTICAL MANUFACTURING SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
  • 4.3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD BILLION)
    • FIGURE 17 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT TO DOMINATE MARKET TILL 2028
  • 4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE, BY END USER, 2022
    • FIGURE 18 BIG PHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.5 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 20 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING AND DEVELOPMENT MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increased investment in precision medicines
      • 5.2.1.2 Patent expiry & increasing demand for generic drugs
    • TABLE 5 IMPENDING PATENT EXPIRY OF BLOCKBUSTER DRUGS, BY YEAR
      • 5.2.1.3 High cost of in-house drug development
    • FIGURE 21 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUNDS FROM DISCOVERY TO LAUNCH, 2010-2020 (USD BILLION)
      • 5.2.1.4 Investments in advanced manufacturing technologies by CDMOs
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Varying regulatory requirements across regions
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising demand for cell & gene therapy
    • TABLE 6 EXPANSIONS BY TOP COMPANIES IN 2022
      • 5.2.3.2 Growing inclination toward one-stop-shop model
      • 5.2.3.3 Market expansion in emerging countries
      • 5.2.3.4 Growth of nuclear medicine
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Introduction of serialization
      • 5.2.4.2 Intellectual property risk
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 22 VALUE CHAIN ANALYSIS: API PRODUCTION AND FORMULATION ADD MAXIMUM VALUE
  • 5.4 ECOSYSTEM ANALYSIS
    • FIGURE 23 ECOSYSTEM ANALYSIS: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • TABLE 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: ROLE IN ECOSYSTEM
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 THREAT OF NEW ENTRANTS
    • 5.6.2 THREAT OF SUBSTITUTES
    • 5.6.3 BARGAINING POWER OF SUPPLIERS
    • 5.6.4 BARGAINING POWER OF BUYERS
    • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 REGULATORY ANALYSIS
    • TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 REGULATORY SCENARIO IN DIFFERENT COUNTRIES
  • 5.8 KEY CONFERENCES & EVENTS, 2022-2023
    • TABLE 14 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2022-2023
  • 5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CDMO SERVICES
    • 5.9.2 BUYING CRITERIA
    • FIGURE 25 KEY BUYING CRITERIA FOR END USERS
  • 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS
    • FIGURE 26 REVENUE SHIFT & NEW POCKETS FOR PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • 5.11 ANDA APPROVALS
    • FIGURE 27 ANDA APPROVALS, 2018-2022
    • FIGURE 28 REGIONAL BREAKDOWN OF ANDA APPROVALS IN 2022
    • FIGURE 29 ANDA APPROVALS IN 2022, BY DOSAGE FORM

6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE

  • 6.1 INTRODUCTION
    • TABLE 15 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
  • 6.2 PHARMACEUTICAL MANUFACTURING SERVICES
    • TABLE 16 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 17 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 18 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 19 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 20 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 21 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • 6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
      • 6.2.1.1 Need to focus on core areas to drive pharma companies to outsource API manufacturing
    • TABLE 22 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 23 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 24 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 25 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 26 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • 6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
    • TABLE 27 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 28 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 29 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 30 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 31 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 32 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
      • 6.2.2.1 Parenteral/Injectable manufacturing services
        • 6.2.2.1.1 Increasing investments in drug development to support market growth
    • TABLE 33 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 34 NORTH AMERICA: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 35 EUROPE: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 36 ASIA PACIFIC: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 37 LATIN AMERICA: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
      • 6.2.2.2 Tablet manufacturing services
        • 6.2.2.2.1 Growing production capacity for tablet manufacturing in emerging markets to support growth
    • TABLE 38 TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 39 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 40 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 41 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 42 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
      • 6.2.2.3 Capsule manufacturing services
        • 6.2.2.3.1 Popularity of capsules to ensure demand for contract manufacturing
    • TABLE 43 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 44 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 45 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 46 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 47 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
      • 6.2.2.4 Oral liquid manufacturing services
        • 6.2.2.4.1 Complexities in handling liquids to promote outsourcing
    • TABLE 48 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 49 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 50 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 51 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 52 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
      • 6.2.2.5 Semi-solid manufacturing services
        • 6.2.2.5.1 Need for specialized facilities to boost outsourcing of semi-solid manufacturing
    • TABLE 53 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 54 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 55 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 56 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 57 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
      • 6.2.2.6 Other FDF manufacturing services
    • TABLE 58 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 59 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 60 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 61 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 62 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
  • 6.3 DRUG DEVELOPMENT SERVICES
    • 6.3.1 HIGH COST OF DEVELOPMENT TO BOOST OUTSOURCING
    • TABLE 63 DRUG DEVELOPMENT SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 64 NORTH AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 65 EUROPE: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 66 ASIA PACIFIC: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 67 LATIN AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
  • 6.4 BIOLOGIC MANUFACTURING SERVICES
    • TABLE 68 BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 69 BIOLOGIC MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 70 NORTH AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 71 EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 72 ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 73 LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • 6.4.1 BIOLOGIC API MANUFACTURING SERVICES
      • 6.4.1.1 Rising interest in biologics to ensure growth of nascent contract manufacturing sector
    • TABLE 74 BIOLOGIC API MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 75 NORTH AMERICA: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 76 EUROPE: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 77 ASIA PACIFIC: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 78 LATIN AMERICA: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • 6.4.2 BIOLOGIC FDF MANUFACTURING SERVICES
      • 6.4.2.1 Growing R&D costs and process complexity to favor contract manufacturing
    • TABLE 79 BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 80 NORTH AMERICA: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 81 EUROPE: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 82 ASIA PACIFIC: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 83 LATIN AMERICA: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD BILLION)

7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER

  • 7.1 INTRODUCTION
    • TABLE 84 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
  • 7.2 BIG PHARMACEUTICAL COMPANIES
    • 7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPIES TO CONTRIBUTE TO MARKET GROWTH
    • TABLE 85 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 86 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 87 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 88 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 89 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
    • 7.3.1 GROWING DEVELOPMENT OF BIOLOGICS AND HIGH PRICING PRESSURE TO BOOST MARKET
    • TABLE 90 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 91 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 92 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 93 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 94 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 7.4 GENERIC PHARMACEUTICAL COMPANIES
    • 7.4.1 RISING DEMAND FOR GENERICS TO PROPEL MARKET
    • TABLE 95 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 96 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 97 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 98 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 99 LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD BILLION)
  • 7.5 OTHER END USERS
    • TABLE 100 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD BILLION)
    • TABLE 101 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 102 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 103 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 104 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD BILLION)

8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 105 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2021-2028 (USD BILLION)
  • 8.2 NORTH AMERICA
    • FIGURE 30 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
    • TABLE 106 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 107 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 108 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 109 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 110 NORTH AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 111 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.2.1 US
      • 8.2.1.1 US to dominate North American market
    • TABLE 112 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 113 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 114 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 115 US: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 116 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.2.2 CANADA
      • 8.2.2.1 Rising government funding and support to propel market
    • TABLE 117 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 118 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 119 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 120 CANADA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 121 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.2.3 NORTH AMERICA: RECESSION IMPACT
  • 8.3 EUROPE
    • TABLE 122 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 123 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 124 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 125 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 126 EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 127 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.1 GERMANY
      • 8.3.1.1 Germany to hold largest share throughout forecast period
    • TABLE 128 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 129 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 130 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 131 GERMANY: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 132 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.2 UK
      • 8.3.2.1 Rising investments in drug development to favor market growth
    • TABLE 133 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 134 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 135 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 136 UK: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 137 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.3 FRANCE
      • 8.3.3.1 Growing generics segment, favorable government policies, and growing clinical trials to drive market
    • TABLE 138 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 139 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 140 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 141 FRANCE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 142 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.4 ITALY
      • 8.3.4.1 Rising commercial drug development pipeline in Europe to favor market growth
    • TABLE 143 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 144 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 145 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 146 ITALY: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 147 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.5 SWITZERLAND
      • 8.3.5.1 Growing pharmaceutical industry to support growth
    • TABLE 148 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 149 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 150 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 151 SWITZERLAND: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 152 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.6 POLAND
      • 8.3.6.1 Increasing support for life science R&D to propel market
    • TABLE 153 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 154 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 155 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 156 POLAND: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 157 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.7 SPAIN
      • 8.3.7.1 Rising R&D expenditure to boost market
    • TABLE 158 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 159 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 160 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 161 SPAIN: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 162 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.8 REST OF EUROPE
    • TABLE 163 REST OF EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 164 REST OF EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 165 REST OF EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 166 REST OF EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 167 REST OF EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.3.9 EUROPE: RECESSION IMPACT
  • 8.4 ASIA PACIFIC
    • FIGURE 31 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
    • TABLE 168 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 169 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 170 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 171 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 172 ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 173 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.4.1 CHINA
      • 8.4.1.1 China to hold largest share of Asia Pacific market
    • TABLE 174 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 175 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 176 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 177 CHINA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 178 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.4.2 INDIA
      • 8.4.2.1 Increasing pharma R&D activities and government funding for biotechnology to support market growth
    • TABLE 179 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 180 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 181 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 182 INDIA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 183 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.4.3 JAPAN
      • 8.4.3.1 Growing generics demand and government initiatives to drive demand for contract manufacturing
    • TABLE 184 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 185 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 186 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 187 JAPAN: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 188 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.4.4 SOUTH KOREA
      • 8.4.4.1 Government initiatives and growing R&D activities for drug development to drive market growth
    • TABLE 189 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 190 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 191 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 192 SOUTH KOREA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 193 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.4.5 REST OF ASIA PACIFIC
    • TABLE 194 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 195 REST OF ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 196 REST OF ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 197 REST OF ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 198 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.4.6 ASIA PACIFIC: RECESSION IMPACT
  • 8.5 LATIN AMERICA
    • TABLE 199 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD BILLION)
    • TABLE 200 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 201 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 202 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 203 LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 204 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.5.1 BRAZIL
      • 8.5.1.1 Growing pharmaceutical industry to drive market
    • TABLE 205 BRAZIL: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 206 BRAZIL: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 207 BRAZIL: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 208 BRAZIL: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 209 BRAZIL: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.5.2 REST OF LATIN AMERICA
    • TABLE 210 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 211 REST OF LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 212 REST OF LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 213 REST OF LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 214 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.5.3 LATIN AMERICA: RECESSION IMPACT
  • 8.6 MIDDLE EAST & AFRICA
    • 8.6.1 UAE AND SAUDI ARABIA TO SHOW SIGNIFICANT GROWTH
    • TABLE 215 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD BILLION)
    • TABLE 216 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 217 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 218 MIDDLE EAST & AFRICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021-2028 (USD BILLION)
    • TABLE 219 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021-2028 (USD BILLION)
    • 8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 KEY PLAYER STRATEGIES
    • TABLE 220 KEY STRATEGIES ADOPTED BY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, 2020-2023
  • 9.3 REVENUE SHARE ANALYSIS
    • FIGURE 32 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2020-2022
  • 9.4 MARKET SHARE ANALYSIS
    • FIGURE 33 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
    • TABLE 221 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEGREE OF COMPETITION
  • 9.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022
    • 9.5.1 STARS
    • 9.5.2 EMERGING LEADERS
    • 9.5.3 PERVASIVE PLAYERS
    • 9.5.4 PARTICIPANTS
    • FIGURE 34 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT, 2022
  • 9.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
    • 9.6.1 SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
    • TABLE 222 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • 9.6.2 END-USER FOOTPRINT OF COMPANIES (25 COMPANIES)
    • TABLE 223 END-USER FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • 9.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
    • TABLE 224 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • 9.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2022)
    • 9.7.1 PROGRESSIVE COMPANIES
    • 9.7.2 STARTING BLOCKS
    • 9.7.3 RESPONSIVE COMPANIES
    • 9.7.4 DYNAMIC COMPANIES
    • FIGURE 35 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2022
  • 9.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES
    • TABLE 225 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
    • TABLE 226 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
  • 9.9 COMPETITIVE SCENARIO AND TRENDS
    • 9.9.1 SERVICE LAUNCHES
    • TABLE 227 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2020-MARCH 2023
    • 9.9.2 DEALS
    • TABLE 228 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEALS, JANUARY 2020-MARCH 2023
    • 9.9.3 OTHER DEVELOPMENTS
    • TABLE 229 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: OTHER DEVELOPMENTS, JANUARY 2020-MARCH 2023

10 COMPANY PROFILES

  • 10.1 KEY MARKET PLAYERS
  • (Business Overview, Services Offered, Recent Developments, and MnM View)**
    • 10.1.1 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 230 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
    • 10.1.2 CATALENT, INC.
    • TABLE 231 CATALENT, INC.: BUSINESS OVERVIEW
    • FIGURE 37 CATALENT, INC.: COMPANY SNAPSHOT (2022)
    • 10.1.3 LONZA GROUP
    • TABLE 232 LONZA GROUP: BUSINESS OVERVIEW
    • FIGURE 38 LONZA GROUP: COMPANY SNAPSHOT (2022)
    • 10.1.4 ABBVIE, INC.
    • TABLE 233 ABBVIE, INC.: BUSINESS OVERVIEW
    • FIGURE 39 ABBVIE, INC.: COMPANY SNAPSHOT (2022)
    • 10.1.5 WUXI APPTEC
    • TABLE 234 WUXI APPTEC: BUSINESS OVERVIEW
    • FIGURE 40 WUXI APPTEC: COMPANY SNAPSHOT (2022)
    • 10.1.6 EVONIK INDUSTRIES AG
    • TABLE 235 EVONIK INDUSTRIES AG: BUSINESS OVERVIEW
    • FIGURE 41 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2022)
    • 10.1.7 SAMSUNG BIOLOGICS
    • TABLE 236 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
    • FIGURE 42 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022)
    • 10.1.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • TABLE 237 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
    • FIGURE 43 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)
    • 10.1.9 SIEGFRIED HOLDING AG
    • TABLE 238 SIEGFRIED HOLDING AG: BUSINESS OVERVIEW
    • FIGURE 44 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2022)
    • 10.1.10 FUJIFILM HOLDINGS CORPORATION
    • TABLE 239 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 45 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
    • 10.1.11 EUROFINS SCIENTIFIC
    • TABLE 240 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
    • 10.1.12 PIRAMAL PHARMA SOLUTIONS
    • TABLE 241 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
    • FIGURE 47 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022)
    • 10.1.13 RECIPHARM AB
    • TABLE 242 RECIPHARM AB: BUSINESS OVERVIEW
    • 10.1.14 ALMAC GROUP
    • TABLE 243 ALMAC GROUP: BUSINESS OVERVIEW
    • 10.1.15 VETTER PHARMA
    • TABLE 244 VETTER PHARMA: BUSINESS OVERVIEW
  • * Business Overview, Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
  • 10.2 OTHER PLAYERS
    • 10.2.1 DELPHARM HOLDINGS
    • 10.2.2 YUHAN CORPORATION
    • 10.2.3 CURIA GLOBAL, INC.
    • 10.2.4 CHARLES RIVER LABORATORIES
    • 10.2.5 LANNETT COMPANY, INC.
    • 10.2.6 CAMBREX CORPORATION
    • 10.2.7 FAMAR HEALTHCARE SERVICES
    • 10.2.8 SYNGENE INTERNATIONAL LIMITED (BIOCON LIMITED)
    • 10.2.9 SAI LIFE SCIENCES LIMITED
    • 10.2.10 PCI PHARMA SERVICES

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 CUSTOMIZATION OPTIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS